Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q46900223

about

Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors Management of patients with hepatic metastases from neuroendocrine tumors Target therapy in metastatic pheochromocytoma: current perspectives and controversies Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer.Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.Progress in the treatment of neuroendocrine tumors.Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group.Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm New treatment options for patients with advanced neuroendocrine tumors.Gastric neuroendocrine tumours.Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.Metastatic paraganglioma.Multimodal management of neuroendocrine liver metastases.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.A preclinical and clinical study of lithium in low-grade neuroendocrine tumors.Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Targeted therapy in advanced well-differentiated neuroendocrine tumors.Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

P2860

Q26752757-601F7F7E-7701-4CC2-B7AB-60E3D852349A Q26753070-0F2D63A6-E1FF-449C-8FA0-CC7E47607C7A Q26765289-F35CC664-FF4B-4317-9B41-4B69546B7FD4 Q26823873-AB4F5A93-2526-48EB-9DDC-8771A6EA7562 Q27008832-E37472BA-310F-4B82-9FC6-4DE62DB3B231 Q28087343-64881A53-8B1D-45BD-9E3C-62C6A988B656 Q28477147-D8ADF841-CC4D-4D7E-A33F-6DD5C81265D9 Q30364864-5EAA08D6-2D06-4D00-8340-AAE4CB55C93C Q31170918-E7B7F3D8-F617-4BCF-9F2A-4A96511A72AC Q33388860-149D196C-FF68-432B-8AD4-F608D5FD94E1 Q33402226-4BC0C178-0B4C-479F-B6C8-2626673E7CA6 Q33405625-B80FD71F-5D1B-4B47-BFB8-7C193926E817 Q33406979-C8126A7E-8FB3-4072-856E-FF673612EBB4 Q33643643-7CFC7BD9-A94E-49FD-A97B-6ABD768BB0E1 Q33700134-3DD07A18-73C7-4EBC-AB65-E6DCF8967CE5 Q33782024-4A82FF4E-0E63-425D-9DDE-DD5BED95165C Q33783119-DFED6ECA-E97A-4E6E-B809-379E9D1431D5 Q33840177-FFBF95A1-C4EF-4061-ACB1-16AEA625A49B Q33894587-57D8B3DA-4E7D-4835-96C0-E9DC4F5E72E4 Q33948026-F3C011F9-3725-43B6-88AD-431D4753FA61 Q34029197-44982982-0E64-4728-8B2A-435D72105030 Q34173336-B556B15F-D04B-4068-A782-AAA31D92E28F Q34306680-D8298EF1-520F-4A97-9BFC-891EFAAE930A Q34410500-741BBE14-3D5D-4157-9A7F-4DD371FA74FB Q34452319-4F7DF6BC-E7D4-4025-8B59-F25341A9A679 Q34480015-F60161CA-3BF9-4649-9192-34B63E170FE9 Q34528199-5406E6CE-30C8-45AE-A0DB-516985EF9957 Q34965132-FF574EF0-8E7A-4CE6-93C5-ECDD363206B2 Q35001754-4233CA0F-6476-4FF7-83CD-654547CB91CD Q35020652-31C8812F-1443-47B8-864F-F7D449DA152B Q35034000-1AD9207F-76EF-4B82-9087-52350EEC75E4 Q35057374-BFFDEC24-792E-4A71-BF88-453244885444 Q35081993-45763E87-86F4-4E9E-81DD-79CE3A6E283F Q35128224-806D99E8-38D0-48F8-BC77-3E3E4EACA4C3 Q35371197-26BF3BFB-B4E9-4DAE-BD4E-64430F7A3FE6 Q35584497-631A6C9E-5DF2-4723-8536-98EEC9B09110 Q35665113-AFD47D15-4EDB-4979-BAE2-D5697C49A0C9 Q35677887-77D20D81-24B1-4537-8E8A-FB8A162EDA9B Q35738251-188EA30F-19C5-496A-925D-AB11D3EB09A4 Q35760798-B8F8D0B4-7A1B-4758-B320-E5CEF002F5A1

P2860

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q46900223

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Phase II study of temozolomide ...... astatic neuroendocrine tumors.

@en

Phase II study of temozolomide ...... astatic neuroendocrine tumors.

@nl

type

label

Phase II study of temozolomide ...... astatic neuroendocrine tumors.

@en

Phase II study of temozolomide ...... astatic neuroendocrine tumors.

@nl

prefLabel

Phase II study of temozolomide ...... astatic neuroendocrine tumors.

@en

Phase II study of temozolomide ...... astatic neuroendocrine tumors.

@nl

P1433

Q46900223-D44A3B79-B95B-4068-99C6-3835A9B182CC

P1476

Q46900223-8E5B333B-D7F7-4A1E-B1DC-7F0F38E02430

P2093

Q46900223-07E6DB9A-C45F-4DF1-8167-1FB41E184275

Q46900223-3864C583-D222-44F2-8418-39D90B75CFB6

Q46900223-4838219F-544A-47C1-9C61-B3CC61DA2C9E

Q46900223-839C844B-EB94-4AF5-A098-587E9800053E

Q46900223-8EB9A007-C6B4-489A-A8ED-523D1CB15C72

Q46900223-9F284516-571E-42ED-99A1-E8AB952D0662

Q46900223-CE970363-6A67-4448-81B7-8D1B79EB35D3

Q46900223-D7B4FDFA-8BCE-4ECB-B38B-13E113918565

P304

Q46900223-01DE3B22-54AF-44D2-92BA-2F38043F051D

P31

Q46900223-CC575D86-6D9C-4863-B9E7-A3CEB87C2D2A

P356

Q46900223-F3229622-5983-4028-BA72-B1AE72FD714C

P407

Q46900223-A19FF06C-22C0-4B09-9184-B5681263722A

P433

Q46900223-1794B524-F1E5-42CC-89E2-AEAD98DB4CDC

P478

Q46900223-691ED30C-4F61-494A-8BAA-04F71991B998

P50

Q46900223-F755B0CA-56FB-47DC-92FA-C632BA4CC9EE

P577

Q46900223-B756E67F-9FE5-4452-9F52-3ADD8404134C

P698

Q46900223-76CE7025-C4B1-4FBA-9FBF-7D1DB4A6FEDC

P921

Q46900223-615364E8-CDAF-40B9-8256-F026BEE7AA98

Q46900223-9D47A66C-4C70-4D4B-86BE-C4E2BD2C5C25

P356

JCO.2005.03.6046

P1433

Journal of Clinical Oncology

P1476

Phase II study of temozolomide ...... astatic neuroendocrine tumors.

@en

P2093

Alona Muzikansky

http://www.w3.org/2001/XMLSchema#string

Ann Michelini

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Clark

http://www.w3.org/2001/XMLSchema#string

Keith Stuart

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

Michele Vincitore

http://www.w3.org/2001/XMLSchema#string

Peter C Enzinger

http://www.w3.org/2001/XMLSchema#string

P304

401-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.03.6046

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16421420

http://www.w3.org/2001/XMLSchema#string

P921